Search

Your search keyword '"Touat, Mehdi"' showing total 399 results
Start Over Author "Touat, Mehdi"
399 results on '"Touat, Mehdi"'

1. Microsatellite instability at U2AF-binding polypyrimidic tract sites perturbs alternative splicing during colorectal cancer initiation

Author

Jonchère, Vincent, Montémont, Hugo, Le Scanf, Enora, Siret, Aurélie, Letourneur, Quentin, Tubacher, Emmanuel, Battail, Christophe, Fall, Assane, Labreche, Karim, Renault, Victor, Ratovomanana, Toky, Buhard, Olivier, Jolly, Ariane, Le Rouzic, Philippe, Feys, Cody, Despras, Emmanuelle, Zouali, Habib, Nicolle, Rémy, Cervera, Pascale, Svrcek, Magali, Bourgoin, Pierre, Blanché, Hélène, Boland, Anne, Lefèvre, Jérémie, Parc, Yann, Touat, Mehdi, Bielle, Franck, Arzur, Danielle, Cueff, Gwennina, Le Jossic-Corcos, Catherine, Quéré, Gaël, Dujardin, Gwendal, Blondel, Marc, Le Maréchal, Cédric, Cohen, Romain, André, Thierry, Coulet, Florence, de la Grange, Pierre, de Reyniès, Aurélien, Fléjou, Jean-François, Renaud, Florence, Alentorn, Agusti, Corcos, Laurent, Deleuze, Jean-François, Collura, Ada, and Duval, Alex

Published
2024
Full Text
View/download PDF

2. A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation

Author

Auffret, Lucie, Ajlil, Yassine, Tauziède-Espariat, Arnault, Kergrohen, Thomas, Puiseux, Chloé, Riffaud, Laurent, Blouin, Pascale, Bertozzi, Anne-Isabelle, Leblond, Pierre, Blomgren, Klas, Froelich, Sébastien, Picca, Alberto, Touat, Mehdi, Sanson, Marc, Beccaria, Kévin, Blauwblomme, Thomas, Dangouloff-Ros, Volodia, Boddaert, Nathalie, Varlet, Pascale, Debily, Marie-Anne, Grill, Jacques, and Castel, David

Published
2024
Full Text
View/download PDF

4. Lynch syndrome: influence of additional susceptibility variants on cancer risk

Author

Vibert, Roseline, Hasnaoui, Jasmine, Perrier, Alexandre, Lefebvre, Alexandra, Colas, Chrystelle, Dhooge, Marion, Basset, Noémie, Chansavang, Albain, Desseignes, Camille, Duval, Alex, Farelly, Solenne, Hamzaoui, Nadim, Laurent-Puig, Pierre, Metras, Julie, Moliere, Diane, Muleris, Martine, Netter, Jeanne, Touat, Mehdi, Bielle, Franck, Labreche, Karim, Nicolle, Romain, Perkins, Géraldine, Warcoin, Mathilde, Coulet, Florence, and Benusiglio, Patrick R.

Published
2023
Full Text
View/download PDF

6. RTID-05. INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF VORASIDENIB (AG-881) VS PLACEBO IN PATIENTS WITH RESIDUAL/RECURRENT GRADE II GLIOMA WITH AN ISOCITRATE DEHYDROGENASE 1/2 (IDH1/2) MUTATION

Author

Mellinghoff, Ingo, van den Bent, Martin, Clarke, Jennifer, Maher, Elizabeth, Peters, Katherine, Touat, Mehdi, de Groot, John, De La Fuente, Macarena, Arrillaga-Romany, Isabel, Wick, Wolfgang, Ellingson, Benjamin, Schoenfeld, Steven, Liu, Hua, Le, Kha, Lu, Min, Steelman, Lori, Hassan, Islam, Pandya, Shuchi, Wen, Patrick, and Cloughesy, Timothy

Subjects
Neurosciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Abstract BACKGROUND Low-grade gliomas (LGGs; WHO grade II) are incurable and ultimately progress to high-grade gliomas. The current treatment options are surgery followed by observation (“watch and wait”) for patients with lower risk for disease progression or postoperative chemoradiotherapy (high-risk population). There are no approved targeted therapies. IDH1 and IDH2 mutations (mIDH1/2) occur in approximately 80% and 4% of LGGs, respectively, and promote tumorigenesis via neomorphic production of D-2-hydroxyglutarate. Vorasidenib, an oral, potent, reversible, brain-penetrant pan-inhibitor of mIDH1/2, was evaluated in 76 patients with glioma in two phase 1 studies (dose escalation and perioperative) and was associated with a favorable safety profile at daily doses below 100 mg. Preliminary clinical activity was observed in non-enhancing glioma patients in both studies, with an objective response rate (ORR) of 18.2% and median progression-free survival of 31.4 months in the dose escalation study. METHODS Approximately 366 patients will be randomized 1:1 to vorasidenib (50 mg QD) or matched placebo and stratified by 1p19q status (intact vs co-deleted). Key eligibility criteria: age ≥ 12 years; grade II oligodendroglioma or astrocytoma (per WHO 2016 criteria) not in need of immediate treatment and without high-risk features; centrally confirmed mIDH1/2 status; ≥ 1 surgery for glioma with most recent ≥ 1 year but ≤ 5 years before randomization, and no other anticancer therapy; Karnofsky performance status ≥ 80%; and centrally confirmed measurable, non-enhancing disease evaluable by magnetic resonance imaging. Crossover from placebo to the vorasidenib arm is permitted upon centrally confirmed radiographic progression per RANO-LGG criteria. Primary endpoint: progression-free survival assessed by independent review. Secondary endpoints: safety and tolerability, tumor growth rate assessed by volume, ORR, overall survival, and quality of life. Clinical data will be reviewed regularly by an independent data monitoring committee. The study is currently enrolling patients in the US, with additional countries planned (NCT04164901).

Published
2020

7. Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma

Author

Mellinghoff, Ingo K, Ellingson, Benjamin M, Touat, Mehdi, Maher, Elizabeth, De La Fuente, Macarena I, Holdhoff, Matthias, Cote, Gregory M, Burris, Howard, Janku, Filip, Young, Robert J, Huang, Raymond, Jiang, Liewen, Choe, Sung, Fan, Bin, Yen, Katharine, Lu, Min, Bowden, Chris, Steelman, Lori, Pandya, Shuchi S, Cloughesy, Timothy F, and Wen, Patrick Y

Subjects
Brain Cancer, Neurosciences, Clinical Trials and Supportive Activities, Clinical Research, Cancer, Genetics, Rare Diseases, Orphan Drug, Brain Disorders, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Antineoplastic Agents, Brain Neoplasms, Dose-Response Relationship, Drug, Enzyme Inhibitors, Female, Glioma, Glycine, Humans, Isocitrate Dehydrogenase, Male, Middle Aged, Mutation, Pyridines, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeDiffuse gliomas are malignant brain tumors that include lower-grade gliomas (LGGs) and glioblastomas. Transformation of low-grade glioma into a higher tumor grade is typically associated with contrast enhancement on magnetic resonance imaging. Mutations in the isocitrate dehydrogenase 1 (IDH1) gene occur in most LGGs (> 70%). Ivosidenib is an inhibitor of mutant IDH1 (mIDH1) under evaluation in patients with solid tumors.MethodsWe conducted a multicenter, open-label, phase I, dose escalation and expansion study of ivosidenib in patients with mIDH1 solid tumors. Ivosidenib was administered orally daily in 28-day cycles.ResultsIn 66 patients with advanced gliomas, ivosidenib was well tolerated, with no dose-limiting toxicities reported. The maximum tolerated dose was not reached; 500 mg once per day was selected for the expansion cohort. The grade ≥ 3 adverse event rate was 19.7%; 3% (n = 2) were considered treatment related. In patients with nonenhancing glioma (n = 35), the objective response rate was 2.9%, with 1 partial response. Thirty of 35 patients (85.7%) with nonenhancing glioma achieved stable disease compared with 14 of 31 (45.2%) with enhancing glioma. Median progression-free survival was 13.6 months (95% CI, 9.2 to 33.2 months) and 1.4 months (95% CI, 1.0 to 1.9 months) for the nonenhancing and enhancing glioma cohorts, respectively. In an exploratory analysis, ivosidenib reduced the volume and growth rates of nonenhancing tumors.ConclusionIn patients with mIDH1 advanced glioma, ivosidenib 500 mg once per day was associated with a favorable safety profile, prolonged disease control, and reduced growth of nonenhancing tumors.

Published
2020

9. Epstein-Barr Virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments

Author

Baron, Marine, primary, Labreche, Karim, additional, Veyri, Marianne, additional, Désiré, Nathalie, additional, Bouzidi, Amira, additional, Seck-Thiam, Fatou, additional, Charlotte, Frédéric, additional, Rousseau, Alice, additional, Morin, Véronique, additional, Nakid-Cordero, Cécilia, additional, Abbar, Baptiste, additional, Picca, Alberto, additional, Le Cann, Marie, additional, Balegroune, Noureddine, additional, Gauthier, Nicolas, additional, Theodorou, Ioannis, additional, Touat, Mehdi, additional, Morel, Véronique, additional, Bielle, Franck, additional, Samri, Assia, additional, Alentorn, Agusti, additional, Sanson, Marc, additional, Roos-Weil, Damien, additional, Haioun, Corinne, additional, Poullot, Elsa, additional, De Septenville, Anne Langlois, additional, Davi, Frédéric, additional, Guihot, Amélie, additional, Boelle, Pierre-Yves, additional, Leblond, Véronique, additional, Coulet, Florence, additional, Spano, Jean-Philippe, additional, Choquet, Sylvain, additional, Autran, Brigitte, additional, and Study group, IDeATIon, additional

Published
2024
Full Text
View/download PDF

10. A Randomized, Double-blind, Phase 3 Study of Vorasidenib Versus Placebo in Patients with Mutant IDH1/2 Diffuse Glioma (INDIGO): Analysis of Health-related Quality of Life, Neurocognition and Seizures (PL5.003)

Author

Peters, Katherine, primary, Mellinghoff, Ingo, additional, Van Den Bent, Martin, additional, Blumenthal, Deborah, additional, Touat, Mehdi, additional, Clarke, Jennifer, additional, Mendez, Joe, additional, Yust-Katz, Shlomit, additional, Mason, Warren, additional, Ducray, Francois, additional, Umemura, Yoshie, additional, Nabors, Burt, additional, Holdhoff, Matthias, additional, Hottinger, Andreas, additional, Arakawa, Yoshiki, additional, Sepúlveda, Juan, additional, Wick, Wolfgang, additional, Soffietti, Riccardo, additional, Perry, James, additional, Giglio, Pierre, additional, De La Fuente, Macarena, additional, Maher, Elizabeth, additional, Bottomley, Andrew, additional, Zhao, Dan, additional, Pandya, Shuchi, additional, Hassan, Islam, additional, Steelman, Lori, additional, Wen, Patrick, additional, and Cloughesy, Timothy, additional

Published
2024
Full Text
View/download PDF

11. Supplementary Table S3 from Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma

Author

Lim-Fat, Mary Jane, primary, Iorgulescu, J. Bryan, primary, Rahman, Rifaquat, primary, Bhave, Varun, primary, Muzikansky, Alona, primary, Woodward, Eleanor, primary, Whorral, Sydney, primary, Allen, Marie, primary, Touat, Mehdi, primary, Li, Xiaomei, primary, Xy, Gongwen, primary, Patel, Jay, primary, Gerstner, Elizabeth R., primary, Kalpathy-Cramer, Jayashree, primary, Youssef, Gilbert, primary, Chukwueke, Ugonma, primary, McFaline-Figueroa, J. Ricardo, primary, Nayak, Lakshmi, primary, Lee, Eudocia Q., primary, Reardon, David A., primary, Beroukhim, Rameen, primary, Huang, Raymond Y., primary, Bi, Wenya Linda, primary, Ligon, Keith L., primary, and Wen, Patrick Y., primary

Published
2024
Full Text
View/download PDF

12. Supplementary Figure S1 from Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma

Author

Lim-Fat, Mary Jane, primary, Iorgulescu, J. Bryan, primary, Rahman, Rifaquat, primary, Bhave, Varun, primary, Muzikansky, Alona, primary, Woodward, Eleanor, primary, Whorral, Sydney, primary, Allen, Marie, primary, Touat, Mehdi, primary, Li, Xiaomei, primary, Xy, Gongwen, primary, Patel, Jay, primary, Gerstner, Elizabeth R., primary, Kalpathy-Cramer, Jayashree, primary, Youssef, Gilbert, primary, Chukwueke, Ugonma, primary, McFaline-Figueroa, J. Ricardo, primary, Nayak, Lakshmi, primary, Lee, Eudocia Q., primary, Reardon, David A., primary, Beroukhim, Rameen, primary, Huang, Raymond Y., primary, Bi, Wenya Linda, primary, Ligon, Keith L., primary, and Wen, Patrick Y., primary

Published
2024
Full Text
View/download PDF

13. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial

Author

Wen, Patrick Y, Touat, Mehdi, Alexander, Brian M, Mellinghoff, Ingo K, Ramkissoon, Shakti, McCluskey, Christine S, Pelton, Kristine, Haidar, Sam, Basu, Sankha S, Gaffey, Sarah C, Brown, Loreal E, Martinez-Ledesma, Juan Emmanuel, Wu, Shaofang, Kim, Jungwoo, Wei, Wei, Park, Mi-Ae, Huse, Jason T, Kuhn, John G, Rinne, Mikael L, Colman, Howard, Agar, Nathalie YR, Omuro, Antonio M, DeAngelis, Lisa M, Gilbert, Mark R, de Groot, John F, Cloughesy, Timothy F, S., Andrew, Roberts, Thomas M, Zhao, Jean J, Lee, Eudocia Q, Nayak, Lakshmi, Heath, James R, Horky, Laura L, Batchelor, Tracy T, Beroukhim, Rameen, Chang, Susan M, Ligon, Azra H, Dunn, Ian F, Koul, Dimpy, Young, Geoffrey S, Prados, Michael D, Reardon, David A, Yung, WK Alfred, and Ligon, Keith L

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Cancer, Brain Cancer, Brain Disorders, Rare Diseases, Clinical Trials and Supportive Activities, Neurosciences, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Aged, 80 and over, Aminopyridines, Antineoplastic Agents, Brain Neoplasms, Chemotherapy, Adjuvant, Disease Progression, Enzyme Activation, Female, Glioblastoma, Humans, Male, Middle Aged, Morpholines, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Phosphatidylinositol 3-Kinase, Phosphoinositide-3 Kinase Inhibitors, Progression-Free Survival, Time Factors, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposePhosphatidylinositol 3-kinase (PI3K) signaling is highly active in glioblastomas. We assessed pharmacokinetics, pharmacodynamics, and efficacy of the pan-PI3K inhibitor buparlisib in patients with recurrent glioblastoma with PI3K pathway activation.MethodsThis study was a multicenter, open-label, multi-arm, phase II trial in patients with PI3K pathway-activated glioblastoma at first or second recurrence. In cohort 1, patients scheduled for re-operation after progression received buparlisib for 7 to 13 days before surgery to evaluate brain penetration and modulation of the PI3K pathway in resected tumor tissue. In cohort 2, patients not eligible for re-operation received buparlisib until progression or unacceptable toxicity. Once daily oral buparlisib 100 mg was administered on a continuous 28-day schedule. Primary end points were PI3K pathway inhibition in tumor tissue and buparlisib pharmacokinetics in cohort 1 and 6-month progression-free survival (PFS6) in cohort 2.ResultsSixty-five patients were treated (cohort 1, n = 15; cohort 2, n = 50). In cohort 1, reduction of phosphorylated AKTS473 immunohistochemistry score was achieved in six (42.8%) of 14 patients, but effects on phosphoribosomal protein S6S235/236 and proliferation were not significant. Tumor-to-plasma drug level was 1.0. In cohort 2, four (8%) of 50 patients reached 6-month PFS6, and the median PFS was 1.7 months (95% CI, 1.4 to 1.8 months). The most common grade 3 or greater adverse events related to treatment were lipase elevation (n = 7 [10.8%]), fatigue (n = 4 [6.2%]), hyperglycemia (n = 3 [4.6%]), and elevated ALT (n = 3 [4.6%]).ConclusionBuparlisib had minimal single-agent efficacy in patients with PI3K-activated recurrent glioblastoma. Although buparlisib achieved significant brain penetration, the lack of clinical efficacy was explained by incomplete blockade of the PI3K pathway in tumor tissue. Integrative results suggest that additional study of PI3K inhibitors that achieve more-complete pathway inhibition may still be warranted.

Published
2019

14. Neuro-Psychological Outcome of ICU-Admitted COVID-19 Patients Presenting With CNS Complications

Author

Pelle, Juliette, Nedelec, Thomas, Marois, Clémence, Delorme, Cecile, Corvol, Jean-Christophe, Delattre, Jean-Yves, Carvalho, Stephanie, Sagnes, Sandrine, Dubois, Bruno, Navarro, Vincent, Louapre, Celine, Stojkovic, Tanya, Idbaih, Ahmed, Rosso, Charlotte, Grabli, David, Gales, Ana Zenovia, Millet, Bruno, Rohaut, Benjamin, Bayen, Eleonore, Dupont, Sophie, Bruneteau, Gaelle, Lehericy, Stephane, Seilhean, Danielle, Durr, Alexandra, Lamari, Foudil, Houot, Marion, Brochard, Vanessa Batista, Lubetzki, Catherine, Seilhean, Danielle, Pradat-Diehl, Pascale, Rosso, Charlotte, Hoang-Xuan, Khe, Fontaine, Bertrand, Naccache, Lionel, Fossati, Philippe, Arnulf, Isabelle, Durr, Alexandra, Carpentier, Alexandre, Edel, Yves, Robain, Gilberte, Thoumie, Philippe, Degos, Bertrand, Sharshar, Tarek, Alamowitch, Sonia, Apartis-Bourdieu, Emmanuelle, Peretti, Charles-Siegried, Ursu, Renata, Dzierzynski, Nathalie, Bourron, Kiyoka Kinugawa, Belmin, Joel, Oquendo, Bruno, Pautas, Eric, Verny, Marc, Samson, Yves, Leder, Sara, Leger, Anne, Deltour, Sandrine, Baronnet, Flore, Bombois, Stephanie, Touat, Mehdi, Idbaih, Ahmed, Sanson, Marc, Dehais, Caroline, Houillier, Caroline, Laigle-Donadey, Florence, Psimaras, Dimitri, Alenton, Agusti, Younan, Nadia, Villain, Nicolas, Grabli, David, del Mar Amador, Maria, Bruneteau, Gaelle, Louapre, Celine, Mariani, Louise-Laure, Mezouar, Nicolas, Mangone, Graziella, Meneret, Aurelie, Hartmann, Andreas, Tarrano, Clement, Bendetowicz, David, Pradat, Pierre-François, Baulac, Michel, Sambin, Sara, Pichit, Phintip, Chochon, Florence, Hesters, Adele, Herlin, Bastien, Nguyen, An Hung, Procher, Valerie, Demoule, Alexandre, Morawiec, Elise, Mayaux, Julien, Faure, Morgan, Ewenczyk, Claire, Coarelli, Giulia, Heinzmann, Anna, Stojkovic, Tanya, Masingue, Marion, Bassez, Guillaume, Navarro, Vincent, An, Isabelle, Worbe, Yulia, Lambrecq, Virginie, Debs, Rabab, Musat, Esteban Munoz, Lenglet, Timothee, Lambrecq, Virginie, Hanin, Aurelie, Chougar, Lydia, Shor, Nathalia, Pyatigorskaya, Nadya, Galanaud, Damien, Leclercq, Delphine, Demeret, Sophie, Rohaut, Benjamin, Cao, Albert, Marois, Clemence, Weiss, Nicolas, Gassama, Salimata, Guennec, Loic Le, Degos, Vincent, Jacquens, Alice, Similowski, Thomas, Morelot-Panzini, Capucine, Rotge, Jean-Yves, Saudreau, Bertrand, Millet, Bruno, Pitron, Victor, Sarni, Nassim, Girault, Nathalie, Maatoug, Redwan, Leu, Smaranda, Bayen, Eleonore, Thivard, Lionel, Mokhtari, Karima, Plu, Isabelle, Gonçalves, Bruno, Bottin, Laure, Yger, Marion, Ouvrard, Gaelle, Haddad, Rebecca, Ketz, Flora, Lafuente, Carmelo, Oasi, Christel, Megabarne, Bruno, Herve, Dominique, Salman, Haysam, Rametti-Lacroux, Armelle, Chalançon, Alize, Herve, Anais, Royer, Hugo, Beauzor, Florence, Maheo, Valentine, Laganot, Christelle, Minelli, Camille, Fekete, Aurelie, Grine, Abel, Biet, Marie, Hilab, Rania, Besnard, Aurore, Bouguerra, Meriem, Goudard, Gwen, Houairi, Saida, Al-Youssef, Saba, Pires, Christine, Oukhedouma, Anissa, Siuda-Krzywicka, Katarzyna, Malkinson, Tal Seidel, Agguini, Hanane, Said, Safia, and Houot, Marion

Published
2023
Full Text
View/download PDF

15. Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma

Author

Coy, Shannon, Wang, Shu, Stopka, Sylwia A., Lin, Jia-Ren, Yapp, Clarence, Ritch, Cecily C., Salhi, Lisa, Baker, Gregory J., Rashid, Rumana, Baquer, Gerard, Regan, Michael, Khadka, Prasidda, Cole, Kristina A., Hwang, Jaeho, Wen, Patrick Y., Bandopadhayay, Pratiti, Santi, Mariarita, De Raedt, Thomas, Ligon, Keith L., Agar, Nathalie Y. R., Sorger, Peter K., Touat, Mehdi, and Santagata, Sandro

Published
2022
Full Text
View/download PDF

17. Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma

Author

Lim-Fat, Mary Jane, primary, Iorgulescu, J. Bryan, additional, Rahman, Rifaquat, additional, Bhave, Varun, additional, Muzikansky, Alona, additional, Woodward, Eleanor, additional, Whorral, Sydney, additional, Allen, Marie, additional, Touat, Mehdi, additional, Li, Xiaomei, additional, Xy, Gongwen, additional, Patel, Jay, additional, Gerstner, Elizabeth R., additional, Kalpathy-Cramer, Jayashree, additional, Youssef, Gilbert, additional, Chukwueke, Ugonma, additional, McFaline-Figueroa, J. Ricardo, additional, Nayak, Lakshmi, additional, Lee, Eudocia Q., additional, Reardon, David A., additional, Beroukhim, Rameen, additional, Huang, Raymond Y., additional, Bi, Wenya Linda, additional, Ligon, Keith L., additional, and Wen, Patrick Y., additional

Published
2024
Full Text
View/download PDF

18. SARS-CoV-2 infection in patients with primary central nervous system lymphoma

Author

Laurenge, Alice, Ursu, Renata, Houillier, Caroline, Abdi, Basma, Tebano, Gianpiero, Quemeneur, Cyril, Choquet, Sylvain, Di Blasi, Roberta, Lozano, Fernando, Morales, Andrea, Durán-Peña, Alberto, Sirven-Villaros, Lila, Mathon, Bertrand, Mokhtari, Karima, Bielle, Franck, Martin-Duverneuil, Nadine, Delattre, Jean-Yves, Marcelin, Anne-Geneviève, Pourcher, Valérie, Alentorn, Agusti, Idbaih, Ahmed, Carpentier, Antoine F., Leblond, Véronique, Hoang-Xuan, Khê, and Touat, Mehdi

Published
2021
Full Text
View/download PDF

19. Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization

Author

Rahman, Rifaquat, primary, Trippa, Lorenzo, additional, Lee, Eudocia Q., additional, Arrillaga-Romany, Isabel, additional, Fell, Geoffrey, additional, Touat, Mehdi, additional, McCluskey, Christine, additional, Wiley, Jennifer, additional, Gaffey, Sarah, additional, Drappatz, Jan, additional, Welch, Mary R., additional, Galanis, Evanthia, additional, Ahluwalia, Manmeet S., additional, Colman, Howard, additional, Nabors, L. Burt, additional, Hepel, Jaroslaw, additional, Elinzano, Heinrich, additional, Schiff, David, additional, Chukwueke, Ugonma N., additional, Beroukhim, Rameen, additional, Nayak, Lakshmi, additional, McFaline-Figueroa, J. Ricardo, additional, Batchelor, Tracy T., additional, Rinne, Mikael L., additional, Kaley, Thomas J., additional, Lu-Emerson, Christine, additional, Mellinghoff, Ingo K., additional, Bi, Wenya Linda, additional, Arnaout, Omar, additional, Peruzzi, Pier Paolo, additional, Haas-Kogan, Daphne, additional, Tanguturi, Shyam, additional, Cagney, Daniel, additional, Aizer, Ayal, additional, Doherty, Lisa, additional, Lavallee, Maria, additional, Fisher-Longden, Brittany, additional, Dowling, Shanna, additional, Geduldig, Jack, additional, Watkinson, Fiona, additional, Pisano, William, additional, Malinowski, Seth, additional, Ramkissoon, Shakti, additional, Santagata, Sandro, additional, Meredith, David M., additional, Chiocca, E. Antonio, additional, Reardon, David A., additional, Alexander, Brian M., additional, Ligon, Keith L., additional, and Wen, Patrick Y., additional

Published
2023
Full Text
View/download PDF

20. A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation

Author

Auffret, Lucie, primary, Ajlil, Yassine, additional, Tauziède-Espariat, Arnault, additional, Kergrohen, Thomas, additional, Puiseux, Chloé, additional, Riffaud, Laurent, additional, Blouin, Pascale, additional, Bertozzi, Anne-Isabelle, additional, Leblond, Pierre, additional, Blomgren, Klas, additional, Froelich, Sébastien, additional, Picca, Alberto, additional, Touat, Mehdi, additional, Sanson, Marc, additional, Beccaria, Kévin, additional, Blauwblomme, Thomas, additional, Dangouloff-Ros, Volodia, additional, Boddaert, Nathalie, additional, Varlet, Pascale, additional, Debily, Marie-Anne, additional, Grill, Jacques, additional, and Castel, David, additional

Published
2023
Full Text
View/download PDF

22. QOL-26. A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF VORASIDENIB VS PLACEBO IN PATIENTS WITH MUTANT IDH1/2DIFFUSE GLIOMA (INDIGO): ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE, NEUROCOGNITION AND SEIZURES

Author

Peters, Katherine, primary, Mellinghoff, Ingo, additional, van den Bent, Martin, additional, Blumenthal, Deborah, additional, Touat, Mehdi, additional, Clarke, Jennifer, additional, Mendez, Joe, additional, Yust-Katz, Shlomit, additional, Mason, Warren, additional, Ducray, Francois, additional, Umemura, Yoshie, additional, Burt Nabors, L, additional, Holdhoff, Matthias, additional, Hottinger, Andreas, additional, Arakawa, Yoshiki, additional, Sepúlveda, Juan, additional, Wick, Wolfgang, additional, Soffietti, Riccardo, additional, Perry, James, additional, Giglio, Pierre, additional, de la Fuente, Macarena, additional, Maher, Elizabeth, additional, Bottomley, Andrew, additional, Zhao, Dan, additional, Pandya, Shuchi, additional, Steelman, Lori, additional, Hassan, Islam, additional, Wen, Patrick, additional, and Cloughesy, Timothy, additional

Published
2023
Full Text
View/download PDF

23. DDDR-09. FUNCTIONAL GENOMICS AND CHEMOTHERAPY RESISTANCE SCREENING IDENTIFIES BIOMARKERS AND TARGETABLE MECHANISMS OF CCNU RESISTANCE IN GLIOMAS

Author

Hajal, Cynthia, primary, Dalin, Simona, additional, Raskind, Greg, additional, Cusick, Margaret, additional, Malinowski, Seth, additional, Ito, Jakob, additional, Bossi, Connor, additional, Vogelzang, Jayne, additional, Bellamy, Charlotte, additional, Salhi, Lisa, additional, Bielle, Franck, additional, Getz, Gad, additional, Bandopadhayay, Pratiti, additional, Touat, Mehdi, additional, Beroukhim, Rameen, additional, and Ligon, Keith, additional

Published
2023
Full Text
View/download PDF

24. CTNI-17. APPLICATION OF THE GBM-X DATA PLATFORM TO ESTIMATE TREATMENT EFFECTS OF THE EXPERIMENTAL THERAPIES OF THE RANDOMIZED PHASE 2 INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPIES

Author

Rahman, Rifaquat, primary, Trippa, Lorenzo, additional, Fell, Geoffrey, additional, Lee, Eudocia, additional, Arrillaga-Romany, Isabel, additional, Touat, Mehdi, additional, Drappatz, Jan, additional, Welch, Mary, additional, Galanis, Evanthia, additional, Ahluwalia, Manmeet, additional, Colman, Howard, additional, Nabors, Burt, additional, Hepel, Jaroslaw, additional, Elinzano, Heinrich, additional, Schiff, David, additional, Chukwueke, Ugonma, additional, Beroukhim, Rameen, additional, Nayak, Lakshmi, additional, McFaline-Figueroa, Jose Ricardo, additional, Batchelor, Tracy, additional, Rinne, Mikael, additional, Kaley, Thomas, additional, Lu-Emerson, Christine, additional, Mellinghoff, Ingo, additional, Bi, Wenya Linda, additional, Arnaout, Omar, additional, Peruzzi, Pier Paolo, additional, Haas-Kogan, Daphne, additional, Tanguturi, Shyam, additional, Cagney, Daniel, additional, Aizer, Ayal, additional, Doherty, Lisa, additional, Santagata, Sandro, additional, Meredith, David, additional, Antonio Chiocca, E, additional, Reardon, David, additional, Alexander, Brian, additional, Ligon, Keith, additional, and Wen, Patrick, additional

Published
2023
Full Text
View/download PDF

25. PATH-12. CONTEMPORARY MOLECULAR LANDSCAPE, SURVIVAL, AND PROGNOSTIC FACTORS IN OVER 4,000 GLIOMAS

Author

Ghosh, Hia, primary, Patel, Ruchit, additional, Woodward, Eleanor, additional, Greenwald, Noah, additional, Bhave, Varun, additional, Maury, Eduardo, additional, Hoffman, Samantha, additional, Li, Yvonne, additional, Gupta, Hersh, additional, Spurr, Liam, additional, Touat, Mehdi, additional, Dubois, Frank, additional, Cherniack, Andrew, additional, Cioffi, Gino, additional, Antonio Chiocca, E, additional, Reardon, David, additional, Wen, Patrick, additional, Meredith, David, additional, Santagata, Sandro, additional, Barnholtz-Sloan, Jill, additional, Ligon, Keith, additional, Beroukhim, Rameen, additional, and Bi, Wenya Linda, additional

Published
2023
Full Text
View/download PDF

26. 638 Characterisation of the immune response to EO2401, a new immunotherapy approach against cancer, plus nivolumab in recurrent glioblastoma: The EOGBM1–18/ROSALIE study

Author

Maia, Ana, primary, Toussaint, Hélène, additional, Magalhaes, Joao Gamelas, additional, Idbaih, Ahmed, additional, Villar, Maria Vieito, additional, Tabatabai, Ghazaleh, additional, Stradella, Agostina, additional, Ghiringhelli, Francois, additional, Burger, Michael C, additional, Mildenberger, Iris, additional, Herrlinger, Ulrich, additional, González, Macarena, additional, Hervieu, Alice, additional, GilMartin, Marta, additional, Renovanz, Mirjam, additional, Touat, Mehdi, additional, Wen, Patrick, additional, Wick, Antje, additional, Bonny, Christophe, additional, Paillarse, Jean-Michel, additional, Reardon, David, additional, Wick, Wolfgang, additional, and Gouttefangeas, Cécile, additional

Published
2023
Full Text
View/download PDF

27. CTIM-25. EO2401 PEPTIDE IMMUNOTHERAPY + NIVOLUMAB +/- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: THE PHASE 1/2 EOGBM1-18/ROSALIE STUDY (NCT04116658)

Author

Reardon, David, primary, Idbaih, Ahmed, additional, Vieito, Maria, additional, Ghiringhelli, François, additional, Stradella, Agostina, additional, Tabatabai, Ghazaleh, additional, Burger, Michael C, additional, Mildenberger, Iris, additional, Herrlinger, Ulrich, additional, Wen, Patrick, additional, Touat, Mehdi, additional, Wick, Antje, additional, González, Macarena, additional, Hervieu, Alice, additional, GilMartin, Marta, additional, Renovanz, Mirjam, additional, Gouttefangeas, Cécile, additional, Maia, Ana, additional, Bonny, Christophe, additional, Paillarse, Jean-Michel, additional, Chêne, Laurent, additional, Fagerberg, Jan, additional, and Wick, Wolfgang, additional

Published
2023
Full Text
View/download PDF

28. CTNI-51. A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF VORASIDENIB VS PLACEBO IN PATIENTS WITH MUTANT IDH1/2 DIFFUSE GLIOMA (INDIGO): EXPLORATORY ANALYSIS OF VARIANT ALLELE FREQUENCY AND PROGRESSION-FREE SURVIVAL

Author

Cloughesy, Timothy, primary, Mellinghoff, Ingo, additional, van den Bent, Martin, additional, Blumenthal, Deborah, additional, Touat, Mehdi, additional, Peters, Katherine, additional, Clarke, Jennifer, additional, Mendez, Joe, additional, Yust-Katz, Shlomit, additional, Mason, Warren, additional, Ducray, Francois, additional, Umemura, Yoshie, additional, Nabors, L Burt, additional, Holdhoff, Matthias, additional, Hottinger, Andreas, additional, Arakawa, Yoshiki, additional, Sepúlveda, Juan, additional, Wick, Wolfgang, additional, Soffietti, Riccardo, additional, Perry, James, additional, Giglio, Pierre, additional, de la Fuente, Macarena, additional, Maher, Elizabeth, additional, Choe, Sung, additional, Zhao, Dan, additional, Pandya, Shuchi, additional, Steelman, Lori, additional, Hassan, Islam, additional, Tron, Adriana, additional, and Wen, Patrick, additional

Published
2023
Full Text
View/download PDF

30. Hippocampal and neocortical BRAF mutant non‐expansive lesions in focal epilepsies

Author

Lerond, Julie, primary, Mathon, Bertrand, additional, Scopin, Mélina, additional, Nichelli, Lucia, additional, Guégan, Justine, additional, Bertholle, Céline, additional, Izac, Brigitte, additional, Andrieu, Muriel, additional, Gareau, Thomas, additional, Donneger, Florian, additional, Mohand Oumoussa, Badreddine, additional, Letourneur, Franck, additional, Tran, Suzanne, additional, Bertrand, Mathilde, additional, Le Roux, Isabelle, additional, Touat, Mehdi, additional, Dupont, Sophie, additional, Poncer, Jean Christophe, additional, Navarro, Vincent, additional, and Bielle, Franck, additional

Published
2023
Full Text
View/download PDF

33. Mechanisms and therapeutic implications of hypermutation in gliomas

Author

Touat, Mehdi, Li, Yvonne Y., Boynton, Adam N., Spurr, Liam F., Iorgulescu, J. Bryan, Bohrson, Craig L., and Cortes-Ciriano, Isidro

Subjects
Antibody diversity -- Analysis, Temozolomide -- Dosage and administration -- Complications and side effects, Gliomas -- Drug therapy, DNA mismatch repair -- Analysis, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

A high tumour mutational burden (hypermutation) is observed in some gliomas.sup.1-5; however, the mechanisms by which hypermutation develops and whether it predicts the response to immunotherapy are poorly understood. Here we comprehensively analyse the molecular determinants of mutational burden and signatures in 10,294 gliomas. We delineate two main pathways to hypermutation: a de novo pathway associated with constitutional defects in DNA polymerase and mismatch repair (MMR) genes, and a more common post-treatment pathway, associated with acquired resistance driven by MMR defects in chemotherapy-sensitive gliomas that recur after treatment with the chemotherapy drug temozolomide. Experimentally, the mutational signature of post-treatment hypermutated gliomas was recapitulated by temozolomide-induced damage in cells with MMR deficiency. MMR-deficient gliomas were characterized by a lack of prominent T cell infiltrates, extensive intratumoral heterogeneity, poor patient survival and a low rate of response to PD-1 blockade. Moreover, although bulk analyses did not detect microsatellite instability in MMR-deficient gliomas, single-cell whole-genome sequencing analysis of post-treatment hypermutated glioma cells identified microsatellite mutations. These results show that chemotherapy can drive the acquisition of hypermutated populations without promoting a response to PD-1 blockade and supports the diagnostic use of mutational burden and signatures in cancer. Temozolomide therapy seems to lead to mismatch repair deficiency and hypermutation in gliomas, but not to an increase in response to immunotherapy., Author(s): Mehdi Touat [sup.1] [sup.2] [sup.3] , Yvonne Y. Li [sup.2] [sup.4] , Adam N. Boynton [sup.2] [sup.5] , Liam F. Spurr [sup.2] [sup.4] , J. Bryan Iorgulescu [sup.4] [sup.6] [...]

Published
2020
Full Text
View/download PDF

35. Exploring the mechanism of 18F‐fluorodopa uptake in recurrent high‐grade gliomas: A comprehensive histomolecular‐positron emission tomography analysis.

Author

Cobes, Nina, Tran, Suzanne, Mathon, Bertrand, Nichelli, Lucia, Bielle, Franck, Touat, Mehdi, Kas, Aurélie, and Rozenblum, Laura

Subjects
BRAIN tumors, GLIOMAS, POSITRON emission tomography, MAGNETIC resonance imaging, TOMOGRAPHY, ISOCITRATE dehydrogenase
Abstract

Background: Dihydroxy‐6‐[18F]fluoro‐L‐phenylalanine (18F‐FDOPA) positron emission tomography (PET) is a valuable tool for managing high‐grade gliomas (HGGs), but there is a lack of literature on its relationship with glioma subtypes since the 2021 reclassification of brain tumors. There is also debate surrounding the mechanism of 18F‐FDOPA uptake, particularly after chemoradiation therapy. This study aimed to investigate the correlation between 18F‐FDOPA uptake and histomolecular characteristics, particularly L‐amino acid transporter 1 (LAT1) expression, in recurrent gliomas, and examine their impact on survival in HGGs. Methods: Thirty‐nine patients with recurrent HGGs (14 isocitrate dehydrogenase [IDH]‐mutant, 25 IDH‐wildtype) who underwent a brain 18F‐FDOPA PET/computed tomography (CT) or PET/magnetic resonance imaging (MRI) followed by surgical resection of the 18F‐FDOPA‐avid lesion within 6 months, were retrospectively reviewed. PET results were compared with histological examination and for SCL7A5/LAT1 immunostaining. The study also examined the relationship between PET parameters, LAT1 expression, and survival outcomes. Results: Astrocytoma IDH‐mutant G4 had higher 18F‐FDOPA uptake than glioblastoma IDH‐wildtype G4 (maximum tumor‐to‐normal brain ratio [TBRmax] 5 [3.4–9] vs. 3.8 [2.8–5.9], p = 0.02). IDH‐mutant gliomas had higher LAT1 expression than IDH‐wildtype gliomas (100 [14–273] vs. 15.5 [0–137], p < 0.05) as well as higher TBRmax (5 [2.4–9] vs. 3.8 [2.8–6], p < 0.05). In survival analysis, LAT1 score >100 was a predictor for longer progression‐free survival in IDH‐mutant HGGs. Conclusions: To our knowledge, our study is the first to suggest a link between LAT1 expression and IDH mutation status. We showed that higher TBRmax was associated with higher LAT1 expression and IDH mutation status. Further studies are needed to better understand the mechanisms underlying amino acid PET tracers uptake, especially in the post‐radiation and chemotherapy settings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE 3 STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1/2 MUTATION

Author

McBain, Catherine, primary, Mellinghoff, Ingo K, additional, van den Bent, Martin J, additional, Blumenthal, Deborah T, additional, Touat, Mehdi, additional, Peters, Katherine B, additional, Clarke, Jennifer, additional, Mendez, Joe, additional, Welsh, Liam, additional, Mason, Warren P, additional, Hottinger, Andreas F, additional, Sepulveda, Juan M, additional, Wick, Wolfgang, additional, Soffetti, Riccardo, additional, Wen, Patrick Y, additional, and Cloughesy, Timothy F, additional

Published
2023
Full Text
View/download PDF

37. Molecular Landscape and Contemporary Prognostic Signatures of Gliomas

Author

Ghosh, Hia S., primary, Patel, Ruchit V., additional, Woodward, Eleanor, additional, Greenwald, Noah F., additional, Bhave, Varun M., additional, Maury, Eduardo A., additional, Cello, Gregory, additional, Hoffman, Samantha E., additional, Li, Yvonne, additional, Gupta, Hersh, additional, Spurr, Liam F., additional, Vogelzang, Jayne, additional, Touat, Mehdi, additional, Dubois, Frank, additional, Cherniack, Andrew D., additional, Guo, Xiaopeng, additional, Tavakol, Sherwin, additional, Cioffi, Gino, additional, Lindeman, Neal I., additional, Ligon, Azra H., additional, Chiocca, E. Antonio, additional, Reardon, David A., additional, Wen, Patrick Y., additional, Meredith, David, additional, Santagata, Sandro, additional, Barnholtz-Sloan, Jill S., additional, Ligon, Keith L., additional, Beroukhim, Rameen, additional, and Bi, Wenya Linda, additional

Published
2023
Full Text
View/download PDF

38. A threshold for mitotic activity and post‐surgical residual volume defines distinct prognostic groups for astrocytoma IDH‐mutant

Author

Tran, Suzanne, primary, Thomas, Alice, additional, Aliouat, Ilyes, additional, Karachi, Carine, additional, Lozano, Fernando, additional, Mokhtari, Karima, additional, Dehais, Caroline, additional, Feuvret, Loïc, additional, Carpentier, Catherine, additional, Giry, Marine, additional, Doukani, Abiba, additional, Lerond, Julie, additional, Marie, Yannick, additional, Sanson, Marc, additional, Idbaih, Ahmed, additional, Carpentier, Alexandre, additional, Hoang‐Xuan, Khê, additional, Touat, Mehdi, additional, Capelle, Laurent, additional, and Bielle, Franck, additional

Published
2023
Full Text
View/download PDF

39. Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma

Author

Spitzer, Avishay, Gritsch, Simon, Nomura, Masashi, Jucht, Alexander, Fortin, Jerome, Raviram, Ramya, Weisman, Hannah R., Gonzalez Castro, L. Nicolas, Druck, Nicholas, Chanoch-Myers, Rony, Lee, John J.Y., Mylvaganam, Ravindra, Lee Servis, Rachel, Fung, Jeremy Man, Lee, Christine K., Nagashima, Hiroaki, Miller, Julie J., Arrillaga-Romany, Isabel, Louis, David N., Wakimoto, Hiroaki, Pisano, Will, Wen, Patrick Y., Mak, Tak W., Sanson, Marc, Touat, Mehdi, Landau, Dan A., Ligon, Keith L., Cahill, Daniel P., Suvà, Mario L., and Tirosh, Itay

Published
2024
Full Text
View/download PDF

43. Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma

Author

Benusiglio, Patrick R., primary, Elder, Fikret, additional, Touat, Mehdi, additional, Perrier, Alexandre, additional, Sanson, Marc, additional, Colas, Chrystelle, additional, Guerrini-Rousseau, Lea, additional, Tran, Duy Thanh, additional, Trabelsi, Nesrine, additional, Carpentier, Catherine, additional, Marie, Yannick, additional, Adam, Clovis, additional, Bernier, Michèle, additional, Cazals-Hatem, Dominique, additional, Mokhtari, Karima, additional, Tran, Suzanne, additional, Mathon, Bertrand, additional, Capelle, Laurent, additional, Dhooge, Marion, additional, Idbaih, Ahmed, additional, Alentorn, Agusti, additional, Houillier, Caroline, additional, Dehais, Caroline, additional, Hoang-Xuan, Khe, additional, Cuzzubbo, Stefania, additional, Carpentier, Antoine, additional, Duval, Alex, additional, Coulet, Florence, additional, and Bielle, Franck, additional

Published
2023
Full Text
View/download PDF

46. DNA repair deficiency sensitizes lung cancer cells to [NAD.sup.+] biosynthesis blockade

Author

Touat, Mehdi, Sourisseau, Tony, Dorvault, Nicolas, Chabanon, Roman M., Garrido, Marlene, Morel, Daphne, Krastev, Dragomir B., Bigot, Ludovic, Adam, Julien, Frankum, Jessica R., Durand, Sylvere, Pontoizeau, Clement, Souquere, Sylvie, Kuo, Mei-Shiue, Sauvaigo, Sylvie, Mardakheh, Faraz, Sarasin, Alain, Olaussen, Ken A., Friboulet, Luc, Bouillaud, Frederic, Pierron, Gerard, Ashworth, Alan, Lombes, Anne, Lord, Christopher J., Soria, Jean-Charles, and Postel-Vinay, Sophie

Subjects
Molecular targeted therapy -- Innovations, Non-small cell lung cancer -- Genetic aspects -- Development and progression -- Care and treatment, DNA repair -- Health aspects, Health care industry
Abstract

Synthetic lethality is an efficient mechanism-based approach to selectively target DNA repair defects. Excision repair cross-complementation group 1 (ERCC1) deficiency is frequently found in non-small-cell lung cancer (NSCLC), making this DNA repair protein an attractive target for exploiting synthetic lethal approaches in the disease. Using unbiased proteomic and metabolic high-throughput profiling on a unique in-house-generated isogenic model of ERCC1 deficiency, we found marked metabolic rewiring of ERCC1-deficient populations, including decreased levels of the metabolite NAD* and reduced expression of the rate-limiting NAD* biosynthetic enzyme nicotinamide phosphoribosyltransferase (NAMPT). We also found reduced NAMPT expression in NSCLC samples with low levels of ERCC1. These metabolic alterations were a primary effect of ERCC1 deficiency, and caused selective exquisite sensitivity to small-molecule NAMPT inhibitors, both in vitro--ERCC1- deficient cells being approximately 1,000 times more sensitive than ERCC1-WT cells--and in vivo. Using transmission electronic microscopy and functional metabolic studies, we found that ERCC1-deficient cells harbor mitochondrial defects. We propose a model where [NAD.sup.+] acts as a regulator of ERCC1-deficient NSCLC cell fitness. These findings open therapeutic opportunities that exploit a yet-undescribed nuclear-mitochondrial synthetic lethal relationship in NSCLC models, and highlight the potential for targeting DNA repair/metabolic crosstalks for cancer therapy., Introduction Despite recent therapeutic advances, non-small-cell lung cancer (NSCLC) remains the leading cause of cancer death (1). Novel effective therapeutic approaches for this aggressive malignancy are therefore urgently required. The [...]

Published
2018
Full Text
View/download PDF

47. Supplementary Figure 5 from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma

Author

Di Stefano, Anna Luisa, primary, Fucci, Alessandra, primary, Frattini, Veronique, primary, Labussiere, Marianne, primary, Mokhtari, Karima, primary, Zoppoli, Pietro, primary, Marie, Yannick, primary, Bruno, Aurelie, primary, Boisselier, Blandine, primary, Giry, Marine, primary, Savatovsky, Julien, primary, Touat, Mehdi, primary, Belaid, Hayat, primary, Kamoun, Aurelie, primary, Idbaih, Ahmed, primary, Houillier, Caroline, primary, Luo, Feng R., primary, Soria, Jean-Charles, primary, Tabernero, Josep, primary, Eoli, Marica, primary, Paterra, Rosina, primary, Yip, Stephen, primary, Petrecca, Kevin, primary, Chan, Jennifer A., primary, Finocchiaro, Gaetano, primary, Lasorella, Anna, primary, Sanson, Marc, primary, and Iavarone, Antonio, primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure 2 from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma

Author

Di Stefano, Anna Luisa, primary, Fucci, Alessandra, primary, Frattini, Veronique, primary, Labussiere, Marianne, primary, Mokhtari, Karima, primary, Zoppoli, Pietro, primary, Marie, Yannick, primary, Bruno, Aurelie, primary, Boisselier, Blandine, primary, Giry, Marine, primary, Savatovsky, Julien, primary, Touat, Mehdi, primary, Belaid, Hayat, primary, Kamoun, Aurelie, primary, Idbaih, Ahmed, primary, Houillier, Caroline, primary, Luo, Feng R., primary, Soria, Jean-Charles, primary, Tabernero, Josep, primary, Eoli, Marica, primary, Paterra, Rosina, primary, Yip, Stephen, primary, Petrecca, Kevin, primary, Chan, Jennifer A., primary, Finocchiaro, Gaetano, primary, Lasorella, Anna, primary, Sanson, Marc, primary, and Iavarone, Antonio, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 1 from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma

Author

Di Stefano, Anna Luisa, primary, Fucci, Alessandra, primary, Frattini, Veronique, primary, Labussiere, Marianne, primary, Mokhtari, Karima, primary, Zoppoli, Pietro, primary, Marie, Yannick, primary, Bruno, Aurelie, primary, Boisselier, Blandine, primary, Giry, Marine, primary, Savatovsky, Julien, primary, Touat, Mehdi, primary, Belaid, Hayat, primary, Kamoun, Aurelie, primary, Idbaih, Ahmed, primary, Houillier, Caroline, primary, Luo, Feng R., primary, Soria, Jean-Charles, primary, Tabernero, Josep, primary, Eoli, Marica, primary, Paterra, Rosina, primary, Yip, Stephen, primary, Petrecca, Kevin, primary, Chan, Jennifer A., primary, Finocchiaro, Gaetano, primary, Lasorella, Anna, primary, Sanson, Marc, primary, and Iavarone, Antonio, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Figure 6 from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma

Author

Di Stefano, Anna Luisa, primary, Fucci, Alessandra, primary, Frattini, Veronique, primary, Labussiere, Marianne, primary, Mokhtari, Karima, primary, Zoppoli, Pietro, primary, Marie, Yannick, primary, Bruno, Aurelie, primary, Boisselier, Blandine, primary, Giry, Marine, primary, Savatovsky, Julien, primary, Touat, Mehdi, primary, Belaid, Hayat, primary, Kamoun, Aurelie, primary, Idbaih, Ahmed, primary, Houillier, Caroline, primary, Luo, Feng R., primary, Soria, Jean-Charles, primary, Tabernero, Josep, primary, Eoli, Marica, primary, Paterra, Rosina, primary, Yip, Stephen, primary, Petrecca, Kevin, primary, Chan, Jennifer A., primary, Finocchiaro, Gaetano, primary, Lasorella, Anna, primary, Sanson, Marc, primary, and Iavarone, Antonio, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results